1. Home
  2. IKT vs SAMG Comparison

IKT vs SAMG Comparison

Compare IKT & SAMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IKT
  • SAMG
  • Stock Information
  • Founded
  • IKT 2008
  • SAMG 2002
  • Country
  • IKT United States
  • SAMG United States
  • Employees
  • IKT N/A
  • SAMG N/A
  • Industry
  • IKT Biotechnology: Pharmaceutical Preparations
  • SAMG Investment Managers
  • Sector
  • IKT Health Care
  • SAMG Finance
  • Exchange
  • IKT Nasdaq
  • SAMG Nasdaq
  • Market Cap
  • IKT 140.5M
  • SAMG 151.1M
  • IPO Year
  • IKT 2020
  • SAMG 2013
  • Fundamental
  • Price
  • IKT $1.71
  • SAMG $16.99
  • Analyst Decision
  • IKT Buy
  • SAMG
  • Analyst Count
  • IKT 2
  • SAMG 0
  • Target Price
  • IKT $8.00
  • SAMG N/A
  • AVG Volume (30 Days)
  • IKT 117.1K
  • SAMG 25.1K
  • Earning Date
  • IKT 08-26-2025
  • SAMG 07-31-2025
  • Dividend Yield
  • IKT N/A
  • SAMG 4.96%
  • EPS Growth
  • IKT N/A
  • SAMG N/A
  • EPS
  • IKT N/A
  • SAMG 0.87
  • Revenue
  • IKT N/A
  • SAMG $124,451,000.00
  • Revenue This Year
  • IKT N/A
  • SAMG $3.93
  • Revenue Next Year
  • IKT N/A
  • SAMG $5.56
  • P/E Ratio
  • IKT N/A
  • SAMG $19.46
  • Revenue Growth
  • IKT N/A
  • SAMG 4.13
  • 52 Week Low
  • IKT $1.12
  • SAMG $13.54
  • 52 Week High
  • IKT $4.20
  • SAMG $19.20
  • Technical
  • Relative Strength Index (RSI)
  • IKT 49.23
  • SAMG 62.75
  • Support Level
  • IKT $1.42
  • SAMG $16.04
  • Resistance Level
  • IKT $1.83
  • SAMG $16.64
  • Average True Range (ATR)
  • IKT 0.15
  • SAMG 0.49
  • MACD
  • IKT 0.00
  • SAMG 0.01
  • Stochastic Oscillator
  • IKT 62.11
  • SAMG 100.00

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

About SAMG Silvercrest Asset Management Group Inc.

Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.

Share on Social Networks: